Hunter Disease

What is MPS II?

MPS II, known as Hunter disease, is one of the mucopolysaccharide storage diseases. MPS II was first identified by Dr Hunter in 1971 and includes a spectrum of symptoms from mild to severe.

Mucopolysaccharides are long chains of sugar molecules used in the building of bones, cartilage, skin, tendons and many other tissues in the body. “Muco” refers to the thick jelly-like consistency of the sugar molecules, “poly” means many, and “saccharide” is a general term for the sugar part of the molecule. In the course of normal life there is a continuous recycling process of building new mucopolysaccharides and breaking down old ones. The breakdown and recycling process requires a series of special biochemical tools called enzymes.

People with MPS II are missing or are low in an enzyme called iduronate 2-sulphatase, which is essential in breaking down mucopolysaccharides dermatan sulphate and heparan sulphate. When dermatan sulphate and heparan sulphate are not completely broken down they remain stored in the body. The symptoms of MPS II are a result of the build-up of dermatan sulphate and heparan sulphate in the tissues in the body. Babies may show little sign of the disease but as more and more cells build-up of partially broken down mucopolysaccharides, symptoms start to appear.

MPS II is an X-linked recessive disease this means that the female are carriers of the affected gene and, apart from very rare cases, only males will be affected by MPS II. It is different for other MPS diseases which are autosomal recessive diseases this means that both parents must carry the same affected gene, and each pass this same affected gene to their child.

People probably carry from 5 to 10 genes with mutations in each of their cells. Problems happen when the particular gene is dominant or when a mutation is present in both copies of a recessive gene pair. Genes are the unique set of instructions inside our bodies that make each of us an individual. They are the blueprint for our growth and development, as well as controlling how our bodies function. Genes are carried on structures called chromosomes and it is usual to have 23 pairs. A child will inherit half of the chromosomes from the mother and the other half from the father resulting in 23 pairs. 22 of these pairs look the same in both males and females. Pair 23 are the sex chromosomes, and this is the pair that differ between females and males. The X chromosome is inherited from the mother and the Y chromosome is inherited from the father. More information about inheritance is available here.

For each pregnancy the chances of a baby inheriting MPS II are completely independent of whether a previous child was affected with MPS II. For a female carrier of MPS II there is a 50% (1:2) risk that any

male born to her will have the disease. Furthermore, there is a 50% (1:2) risk that any female born to her will be a carrier for the disease. The sisters and maternal aunts of a male with MPS II may be carriers of the disease and would also have the same risk of passing the affected gene to any male born to them.

All parents of children with MPS II can benefit from genetic counselling, the counsellor can provide advice on the risk to close relatives and to suggest whether the wider family should be informed. To find out during a pregnancy, if the baby is affected by MPS II, screening tests can be arranged early on during a pregnancy for those families who already have a child with MPS II. Carrier screening is an option for females but it is not 100% reliable or accurate and is not possible in all cases. Amniocentesis and chorionic villus sampling are both available during the pregnancy to find out if the baby is affected by MPS II.

It might also be possible to have Pre-implantation genetic diagnosis (PGD) screening to avoid passing MPS II to the baby. PGD is an assisted fertility treatment that involves checking the chromosomes of embryos before they are transferred in the womb using IVF techniques.



Mucopolysaccharidosis type 2 (MPS2) prevalence at birth in Europe is 1/166,000. It is an X-linked recessive disorder; very rare cases of female presentation have been reported.

People with MPS II can experience some or many symptoms from a wide spectrum which range from severe to very mild. Historically MPS II had been described as either mild or severe, however based on current understanding of the enzyme and its gene, MPS II comprises a wide spectrum of symptoms and severity. Some people with MPS II will have progressive developmental delay and severe progressive physical problems. Others will have normal intelligence and progressive physical problems, some being more severely affected than others. It is important to remember that MPS II is extremely varied in its effects and may even vary in its effects between siblings and generations. For more information about the specific symptoms click through each of the symptom links below.

Hier fehlt noch die verlinkten Icon-Liste.

Enzyme Replacement Therapy (ERT)

For people with MPS II ERT is a long-term therapy whereby the missing or deficient enzyme is given via an intravenous infusion. The name for the replacement enzyme in MPS II is idursulfase and the brand name is Elaprase®. Elaprase® was licensed as an ERT in 2007 and has been shown to reduce many of the non-brain related symptoms, such as improving respiratory function and mobility and reducing joint stiffness.

Elaprase ® is a weekly infusion lasting between 1 to 3 hours that can be administered at home. More information about Elaprase ® can be found at and a UK version of the patient information leaflet is here. Further information on this treatment is available from the electronic medicines compendium.

For an up-to-date list of current UK based trials taking place visit Be Part of Research (resource provided by the National Institute for Health Research). For an international search visit Clinical Trials (resource provided by the U.S. National Library of Medicine). This resource provides information on trial status including recruiting, completed or withdrawn and worldwide trial locations. To find out more about past or current trials speak to your doctor and learn about the risks and potential benefits.

The MPS Society is the only UK charity at the forefront of supporting people and families affected by MPS and related diseases. Our extensive support services offers you a wide range of support and resources. The team can advise and sign post you to adequate needs-led support and services in your local area as well as social care, home adaptions, education and much more. The support team can visit you in your home and provide you with vital support and includes an Advocacy Officer based at Belfast City Hospital supporting members in Northern Ireland.

Get involved and support us in the community, volunteer or support fundraising; the MPS are a small charity but with your support we can continue to offer a highly valued and essential service.

*Content used with courtesy of MPS Society UK